Search Results for: Animal products for pharmaceutical purposes
to august , gsk unlawfully promoted paxil for treating depression in patients under age , even though the fda has never approved it for pediatric use. the united states alleges that, among other things, gsk participated in preparing, publishing and distributing a misleading medical journal article that
to misbranding paxil in that its labeling was false and misleading regarding the use of paxil for patients under . wellbutrin: the united states also alleges that, from january to december , gsk promoted wellbutrin, approved at that time only for major depressive disorder, for weight loss, the treatment...
https://www.justice.gov/opa/pr/glaxosmithkline-plead-guilty-and-pay-3-billion-resolve-fraud-allegations-and-failure-report